Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-02
DOI
10.1038/s41375-021-01183-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
- (2020) Heinz Gisslinger et al. Lancet Haematology
- Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden
- (2020) Theodoros Karantanos et al. Blood Advances
- Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses
- (2018) Tsewang Tashi et al. LEUKEMIA
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
- (2018) Tiziano Barbui et al. LEUKEMIA
- Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
- (2018) Natasha Szuber et al. AMERICAN JOURNAL OF HEMATOLOGY
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- Myeloproliferative Neoplasms
- (2017) Jerry L. Spivak NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12
- (2016) Samer A. Srour et al. BRITISH JOURNAL OF HAEMATOLOGY
- Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials
- (2016) Richard T. Silver et al. Hematology
- Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
- (2015) Alberto Alvarez-Larrán et al. BRITISH JOURNAL OF HAEMATOLOGY
- Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?
- (2015) Hans Carl Hasselbalch et al. Expert Review of Hematology
- Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis
- (2013) R. T. Silver et al. BLOOD
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
- (2013) Richard T Silver et al. Expert Review of Hematology
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant interferon- may retard progression of early primary myelofibrosis: a preliminary report
- (2011) R. T. Silver et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More